Trial Profile
Evaluation of the effect of Angiotensin ll receptor blocker for plaque vulnerability after percutaneous coronary intervention (PCI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2017
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary) ; Antihypertensives
- Indications Atherosclerosis; Hypertension
- Focus Pharmacodynamics
- 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
- 23 Feb 2009 New trial record.